<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02038309</url>
  </required_header>
  <id_info>
    <org_study_id>PPRACS</org_study_id>
    <nct_id>NCT02038309</nct_id>
  </id_info>
  <brief_title>Persistent Platelet Reactivity in Acute Coronary Syndrome</brief_title>
  <official_title>Persistent Platelet Reactivity in Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital Lariboisière</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hopital Lariboisière</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of persistent platelet reactivity during acute coronary syndrome. Patients are included&#xD;
      at admission to the hospital. Platelet aggregation is evaluated by platelet function testing&#xD;
      after blood sampling during hospitalization. No changes in treatment is planned.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Blood samples are performed on day 2 and 4 and collected with usual blood samples and&#xD;
      analyzed by the laboratory. Maximal aggregation intensity and velocity are measured by light&#xD;
      transmission aggregometry induced by arachidonic acid (AA) or adenosine diphosphate (ADP).&#xD;
      Platelet function analyzer will be also used. No changes in treatment in response to the&#xD;
      results is planned.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>maximum aggregation intensity</measure>
    <time_frame>day 2</time_frame>
    <description>Light transmission aggregometry following exposition to arachidonic acid 0.5mg/ml during the acute phase (day2-day 5)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum aggregation intensity</measure>
    <time_frame>Day 2</time_frame>
    <description>Light transmission aggregometry following exposition to adenosine diphosphate during the acute phase (day2-day 5) and during the chronic phase (day 30-day 60)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum aggregation intensity</measure>
    <time_frame>Chronic phase (day 30 to day 60)</time_frame>
    <description>Light transmission aggregometry following exposition to arachidonic acid 0.5mg/ml during the chronic phase (day 30-day 60)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Major cardiovascular and cerebrovascular events (MACCE)</measure>
    <time_frame>one year</time_frame>
    <description>Major cardiovascular and cerebrovascular events : death, myocardial infarction, stroke, rehospitalisation and bleeding (academic research consortium) events at 1 year</description>
  </other_outcome>
  <other_outcome>
    <measure>microvascular resistance index</measure>
    <time_frame>Day 1</time_frame>
    <description>measurement during primary PCI on admission</description>
  </other_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Acute coronary syndrome&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  acute coronary syndrome with elevation in troponin&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  anticoagulant treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Henry, MD-PhD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Cardiology - Lariboisiere Hospital - APHP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiology - Lariboisiere Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JEAN-GUILLAUME DILLINGER, MD</last_name>
      <phone>33620393260</phone>
      <email>dillingerjg@aol.com</email>
    </contact>
    <investigator>
      <last_name>Jean-Guillaume Dillinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>January 12, 2014</study_first_submitted>
  <study_first_submitted_qc>January 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2014</study_first_posted>
  <last_update_submitted>January 15, 2014</last_update_submitted>
  <last_update_submitted_qc>January 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hopital Lariboisière</investigator_affiliation>
    <investigator_full_name>Dr Jean-Guillaume DILLINGER</investigator_full_name>
    <investigator_title>Department of Cardiology</investigator_title>
  </responsible_party>
  <keyword>Acute coronary syndrome</keyword>
  <keyword>persistent platelet reactivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

